clinical trial · NCT04660539
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Hoffmann-La Roche·phase3·completed·n = 119
Neuromyelitis Optica Spectrum Disordersatralizumabazathioprine (AZA)mycophenolate mofetil (MMF)oral corticosteroids
brief summary
This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of studies BN40898 and BN40900. Participants will receive satralizumab as monotherapy or in combination with one of the following background immunosuppressive treatments: azathioprine (AZA), mycophenolate mofetil (MMF), or oral corticosteroids.
started
Mar 2, 2021
primary completion
May 28, 2024
completion
May 28, 2024
last updated
Dec 27, 2024
official title
A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol